Trial Profile
Antihypertensive Effect of Different Doses of Rostafuroxin in Comparison With Losartan, Assessed by Office and Ambulatory Blood Pressure Monitoring in a Hypertensive Population Selected According to a Specific Genetic Profile
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs Rostafuroxin (Primary) ; Losartan
- Indications Essential hypertension
- Focus Proof of concept; Therapeutic Use
- Acronyms PEARL-HT
- 13 Sep 2020 Results presented at the Hypertension Scientific Session 2020.
- 16 Aug 2019 Planned number of patients changed from 240 to 280.
- 08 Aug 2019 Status changed from not yet recruiting to completed.